Frequently Asked Questions About Asacol (Mesalamine)
1.What is Asacol (Mesalamine)?
2.How Does Asacol Work?
3.What Conditions Does Asacol Treat?
4.Is Asacol the Same as Mesalamine?
5.In What Forms is Asacol Available?
6.Can Asacol Be Used for Crohns Disease?
7.How Long Until Asacol Shows Therapeutic Effects?
8.Can Asacol Be Used During Pregnancy?
9.Can Asacol Be Used While Breastfeeding?
10.What Should I Do If I Miss a Dose of Asacol?
11.Does Asacol Have Side Effects?
12.Can Asacol Cause Allergic Reactions?
13.Is Alcohol Consumption Safe While Using Asacol?
14.Can Asacol Interact with Other Medications?
15.How Long Should I Take Asacol?
16.Can Asacol Cause Sun Sensitivity?
17.Can Asacol Be Used in Children?
18.Can Asacol Be Used for Diverticulitis?
19.Is Asacol Available Over-the-Counter?
20.Can Asacol Cause Hair Loss?
21.Can Asacol Be Used for Microscopic Colitis?
22.Can Asacol Cause Weight Gain?
23.Can Asacol Be Used for Eosinophilic Colitis?
24.Can Asacol Tablets Be Split or Crushed?
25.Can Asacol Be Used for Proctitis?
26.Can Asacol Cause Kidney Problems?
27.Can Asacol Be Used for Pouchitis?
28.Can Asacol Cause Elevated Liver Enzymes?
29.Can Asacol Be Used for Ankylosing Spondylitis?
30.Can Asacol Be Used for Sclerosing Cholangitis?
📚 Sources Used for FAQ Content:
Information on mesalamine (the active ingredient in Asacol) is drawn from regulatory approvals across major markets, gastroenterology treatment guidelines for inflammatory bowel disease (IBD), ECCO (European Crohn's and Colitis Organisation) consensus documents, and clinical experience accumulated since the medication's approval in 1992. Asacol was originally developed by Procter & Gamble Pharmaceuticals - now marketed by Allergan/AbbVie - as a delayed-release oral formulation of 5-aminosalicylic acid (5-ASA) targeting the distal small bowel and colon.- U.S. FDA - Asacol approved 1992 for ulcerative colitis; Asacol HD added 2008
- European Medicines Agency (EMA) - Mesalazine approved across EU member states
- UK MHRA - Regulatory oversight; multiple mesalazine products available
- Health Canada, Australia TGA, Japan PMDA - Major global regulators
- WHO Essential Medicines List - Listed for inflammatory bowel disease
- Allergan / AbbVie - Current Asacol brand holder (acquired from Warner Chilcott / P&G)
- Multiple generics - Mesalamine widely available as generic equivalent
- American College of Gastroenterology (ACG) - Ulcerative colitis management guidelines
- American Gastroenterological Association (AGA) - Mild-moderate UC treatment recommendations
- ECCO (European Crohn's and Colitis Organisation) - European IBD consensus standards
- British Society of Gastroenterology (BSG) - UK IBD management guidelines
- Asia Pacific consensus on IBD - Regional treatment standards
- NICE (UK) - Health economic evaluations and clinical guidelines
- Crohn's & Colitis Foundation - Patient-oriented guidance and clinical resources
- 30+ years of clinical experience with mesalamine in IBD
- ASCEND trial program - Established Asacol HD efficacy in moderate UC
- Cochrane systematic reviews - Mesalamine for UC induction and maintenance
- SUCCESS, MANTRA registry data - Long-term real-world outcomes
- ECCO/MSG trial networks - European IBD research consortium
- UpToDate, DynaMed, BNF - Clinical decision support databases
- FDA FAERS, EMA EudraVigilance - Post-marketing surveillance for rare effects
- LiverTox (NIH) - Drug-induced liver injury resource for hepatic monitoring
Note: brand Asacol and generic mesalamine products are bioequivalent within the same formulation family. Different mesalamine BRANDS (Asacol vs Lialda vs Pentasa vs Apriso) have different release pharmacokinetics and are NOT interchangeable - each targets different parts of the GI tract.
FAQ Reviewed and Referenced By:
The Medication Guide content for Asacol reflects published research and clinical guidance from internationally recognised authorities in gastroenterology and inflammatory bowel disease (IBD) management. The expert panel emphasises gastroenterologists with deep experience in ulcerative colitis and Crohn's disease - the conditions where Asacol has its primary role.
Icahn School of Medicine at Mount Sinai - New York, USA
Burrill B. Crohn Professor of Medicine and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Internationally recognised authority on inflammatory bowel disease. Major investigator in landmark UC and Crohn's disease trials including mesalamine-comparator studies.
Northwestern University Feinberg School of Medicine - Chicago, USA
Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center. Past Chair of the Crohn's & Colitis Foundation National Scientific Advisory Committee. Lead investigator on multiple pivotal mesalamine trials including the ASCEND program for Asacol HD.
University of California San Diego School of Medicine - La Jolla, USA
Professor of Medicine and Chief of the Division of Gastroenterology. Major contributor to IBD clinical trials over four decades. Past President of the American Gastroenterological Association. Extensive publications on mesalamine pharmacokinetics, dosing optimisation, and comparative effectiveness.
IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University - Milan, Italy
Head of the Gastroenterology and Endoscopy Department. Past President of the European Crohn's and Colitis Organisation (ECCO). Editor-in-chief of multiple IBD journals. Major European authority on IBD therapeutic algorithms including mesalamine positioning in modern treatment.
University College Cork, APC Microbiome Ireland - Cork, Ireland
Director of APC Microbiome Ireland Research Centre. Former Professor of Gastroenterology at the University of Birmingham (UK) and University of Calgary. Major international IBD authority with extensive publications on mesalamine, biologics, and microbiome-IBD interactions.
Note: this panel reflects published evidence and guidance from the listed authorities; it does not imply individual endorsement of this specific medication guide.
More Anti-Inflammatory Medications
